For young, healthy people who may be wondering, “do I need a COVID booster at all?”, having one annually is sensible.

Moderna has reported top-line data suggesting that its COVID-19 booster vaccine candidate stimulates a strong immune response against the Omicron subvariants BA.4 and BA.5, which have driven an ...

Moderna has started human trials of an Omicron version of its COVID-19 vaccine SpikeVax, just in case a modified version will be needed to boost protection against the new variant later this year.

Stock markets around the world have fallen after the boss of Moderna cast doubts on the effectiveness of vaccines against the new Omicron Covid variant. Stephane Bancel told the Financial Times he ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Moderna Inc. said Thursday a Phase 3 trial of ... which showed that mRNA-1283 had higher neutralizing antibody responses ...

The Moderna laboratories Tuesday reported that their two bivalent Omicron-targeting new messenger RNA (mRNA) technology booster vaccines (mRNA-1273.214 and mRNA-1273.222) have a superior antibody ...

Moderna said in a news release Tuesday that the company’s “next generation Covid-19 vaccine,” has shown a higher immune response to the virus than the current version of the shot. The new vaccine ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...

Health officials say eligible residents can receive the COVID-19 vaccine at the same time as or at any time before or after ...

The Omicron variant has been shaking the stock ... which was enough to erase $15 billion in Moderna’s market cap. “We see MRNA as a better short-term bet on COVID-19 developments.

The updated vaccine covers all major COVID variants that have developed so far, including previous Omicron strains and the new JN1 variant. Thanks to the flexibility of mRNA technology ...